Patent intelligence · WO
WO 2025260285
CONJUGUÉ ANTICORPS-MÉDICAMENT
CONJUGUÉ ANTICORPS-MÉDICAMENT
Patent details — WO 2025260285
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Dec 26, 2025
- Expiration
- Dec 21, 2045
- Applicant
- DUALITY BIOLOGICS SUZHOU CO LTD [CN]
- CPC classes
- A61K 47/ 68 A I, A61K/4768037
Quick answer
WO 2025260285 (CONJUGUÉ ANTICORPS-MÉDICAMENT) is held by DUALITY BIOLOGICS SUZHOU CO LTD [CN]. Status: granted. Granted Dec 26, 2025. Expires Dec 21, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DUALITY BIOLOGICS SUZHOU CO LTD [CN]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 68 A I, A61K/4768037
More from DUALITY BIOLOGICS SUZHOU CO LTD [CN]
Related pharmaceutical patents in our USPTO index.
-
WO 2026082899
ARN POUR LA PREVENTION OU LE TRAITEMENT DE LA TUBERCULOSE
granted -
WO 2026068864
DOMAINES CH1 ET CL MODIFIÉS POUR LA PRÉVENTION DU MÉSAPPARIEMENT DE CHAÎNE
granted -
WO 2026062193
COMPOSITIONS ET PROCÉDÉS
granted -
WO 2026062071
ANTAGONISTES DE TNFR1 ET AGONISTES DE TNFR2 POUR LE TRAITEMENT DE LA DOULEUR AIGUË
granted -
WO 2026057625
PEPTIDOGLYCANE HYDROLASES AYANT UN DOMAINE CHAP AVEC SITE ACTIF MODIFIÉ
granted -
WO 2026058153
UTILISATIONS DE RÉCEPTEUR DE LYMPHOCYTES T DE VPH-16 ET COMPOSITIONS ASSOCIÉES
granted -
WO 2026057739
POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET DES ANTICORPS ANTI-PD-1 POUR LE TRAITEMENT DU CANCER DE L'OVAIRE RÉSISTANT AU PLATINE
granted -
WO 2026057626
PEPTIDOGLYCANE HYDROLASES AYANT DE MULTIPLES DOMAINES ENZYMATIQUEMENT ACTIFS
granted
Frequently asked questions
What is US patent 2025260285?
WO 2025260285 (CONJUGUÉ ANTICORPS-MÉDICAMENT) is held by DUALITY BIOLOGICS SUZHOU CO LTD [CN]. Status: granted. Granted Dec 26, 2025. Expires Dec 21, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025260285?
DUALITY BIOLOGICS SUZHOU CO LTD [CN] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025260285 expire?
Our index shows an expiration date of Dec 21, 2045 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.